

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 November 2003 (06.11.2003)

PCT

(10) International Publication Number
WO 03/091261 A1

(51) International Patent Classification⁷: C07D 501/22

(74) Common Representative: RANBAXY LABORATORIES LIMITED; c/o Deshmukh, Jayadeep, R., 600 College Road East, Princeton, NJ 08540 (US).

(21) International Application Number: PCT/IB02/01410

(22) International Filing Date: 26 April 2002 (26.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): RANBAXY LABORATORIES LIMITED [IN/IN]; 19, Nehru Place, New Delhi 110 019 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KUMAR, Yatendra [IN/IN]; U-25/5, Phase - III, DLF Qutab Enclave, Gurgaon, Haryana 122 001 (IN). PRASAD, Mohan [IN/IN]; P-3/3 Phase - II, DLF Qutab Enclave, Gurgaon, Haryana 122 002 (IN). PRASAD, Ashok [IN/IN]; 147/9 Dr. Gupta's Flat, Kishangarh, Vasant Junj, New Delhi 110 070 (IN). SINGH, Shailendra, Kumar [IN/IN]; A-35/30, Phase-I, DLF Qutab Enclave, Gurgaon, Haryana 122 001 (IN). KUMAR, Neela, Praveen [IN/IN]; House No. 16-2-705/9/A/8, Professors Colony, Malakpet, Hyderabad, 500036 Andhra Pradesh (IN).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PREPARATION OF CEFDINIR

(57) Abstract: The present invention relates to a process for the preparation of cefdinir on an industrial scale.

WO 03/091261 A1


PROCESS FOR THE PREPARATION OF CEFDINIR

Field of the Invention

The present invention relates to an improved process for the preparation of cefdinir on an industrial scale.

Background of the Invention


Cefdinir is chemically known as 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) of



Formula I


Formula I and was described for the first time in U.S. Patent No. 4,559,334. It is the third generation cephalosporin antibiotic for oral administration and has a broader antibacterial spectrum than other orally administrable antibiotics. Cefdinir is particularly effective against staphylococci and streptococci.

Several processes have been reported for the preparation of cefdinir. U.S. Patent No. 4,559,334 describes a process for preparing cefdinir comprising coupling 7-amino-3-vinyl-3-cephem-4-carboxylic acid ester (7-AVCA ester) of Formula P(i),




Formula P(i)

with a reactive derivative of an open chain carboxylic acid of Formula P(ii),



Formula P (ii)

and the resultant 7-amido compound is treated with a nitrosating agent to give an N-oxime compound of Formula P(iii),



Formula P (iii)

which is then cyclized with thiourea and the carboxyl protecting group is removed to obtain cefdinir. The process is expensive as it involves a number of steps using costly starting compound 7-AVCA.

Japanese patent application 2/790 describes a method involving reacting silylated 7-AVCA with acyloxyiminoacetylhalides followed by removal of acyl group from the condensed product to obtain cefdinir. However, the process requires rigorous anhydrous conditions for the condensation step. Moreover, the preparation of starting compound, requires several synthetic steps and includes the use of phosphorous pentoxide thus making the process unsuitable for production at an industrial scale.


Japanese patent application JP 4/173781 uses formyl protected carboxylic acid which is converted in situ to the acid chloride with phosphorous oxychloride and then coupled with carboxyl protected 7-AVCA of Formula P(i), wherein R is a

carboxyl protecting group. The coupled product gives cefdinir in only 22% yield after two successive deprotection steps for removing the formyl group and the carboxyl protecting group, respectively. The use of phosphorous oxychloride is hazardous and highly undesirable at a commercial scale and the low yields due to a large number of steps make the process commercially unattractive.

WO 92/7840 and Japanese patent application JP1/238587 also describes similar processes for preparing cefdinir wherein a carboxyl protected 7-AVCA of Formula P(i) is coupled with an activated ester of 2-aminothiazolyl hydroxyiminoacetamidocarboxylic acid, the amino or the hydroxy group of which are suitably protected. The processes are uneconomical due to several protection and deprotection steps thereby resulting in low overall yields.

WO 01/79211 describes a process for preparing cefdinir, wherein the protecting groups at the carboxyl, hydroxyimino, and amino positions are removed by a mixture of an organic protonic acid and a perhalogenic acid. The use of perhalogenic acid at large scale is undesirable.

U.S. Patent No. 6,093,814 discloses a process for preparing cefdinir wherein reactive ester of Formula P(iv),




Formula P(iv)

wherein Z is the acid active
7-AVCA of Formula P (v)

5

10 in the presence of N, N-dimethyl-4-aminopyridine
isolated in high yield as p-toluenesulfonate
trityl cefdinir of Formula P(v)

15



20

which is treated with an acid

Isolation of the compound
volumes of anti-solvent. C

25

No. 6,093,814 has a low amount of
99.1% (by HPLC). This is
polymerization under the reaction
P(vi) to cefdinir. Also, the
distilling out the high boiling

30

large scale.

Therefore, there still
process for the manufacture
We have now found that tr


ious condition for hydrolysis of compound of Formula
 alk-up procedure is cumbersome and often requires
 acids under reduced pressure, which is difficult at

exists a need for a simple, efficient and cost effective
 of cefdinir of desired purity at a commercial scale.
 d cefdinir forms good crystalline DMAC solvated acid

PCT/IB02/01410


4

ing group and Ph represents phenyl, is coupled with



Formula P(v)

thylacetamide (DMAC), and the coupled product is
 uene sulfonic acid addition salt of a DMAC solvate of



Formula P(vi)

to give cefdinir.

ound of formula P(vi) requires addition of large
 fdinir obtained following the teachings of U.S. Patent
 say of 90 – 91% while showing a qualitative purity of
 ne to the formation of degradation products and


addition salts with methanesulfonic acid and sulfuric acid. These salts are easily crystallized out from the reaction mixture without using excess of antisolvents unlike the p-toluene sulfonic acid salt, and their conversion to cefdinir requires very mild conditions yielding pure cefdinir.

5

Summary of the Invention

It is an object of the present invention to provide a process for the preparation of cefdinir of Formula I,

10




15

Formula I

which comprises removing a trityl protecting group in a cefdinir intermediate of Formula II

20




Formula II

25




wherein A is sulfuric acid or methanesulfonic acid, $n = 2$ or 3 , DMAC is N, N-dimethylacetamide and Ph is phenyl, in the presence or absence of an acid.

The cefdinir intermediate compound of Formula II are crystalline compounds and are in the form of a complex with a salt and a solvent. These can be prepared by reacting a reactive ester having the following Formula P(iv),



Formula P(iv)


in which Ph represents phenyl, Z represents



or



wherein R' represents C₁-C₄ alkyl or phenyl or R' together with phosphorus and oxygen atoms to which R' is attached can form a 5 to 6-membered heterocycle, which is reacted with a 3-cephem derivative having the following Formula P(v),



Formula P(v)

in a solvent comprising N, N-dimethylacetamide (DMAC) in the presence or
absence of a base, cooling the reaction mixture to about -10 to 0°C and then
adding sulfuric acid / methanesulfonic acid slowly, maintaining the temperature
below 0°C. An antisolvent is then added, the temperature of the mixture is raised
to about 30 to 45°C and the mixture is stirred at the same temperature to
crystallize out the compounds of Formula II in good yield and purity.

The reactive ester compound of formula P(iv) and the 3-cephem derivative
of formula P(v) are known compounds and can be prepared according to the
processes disclosed in European Patent laid-open Publication No. 555,769 and
U.S. Patent No. 4,423,213, which are hereby incorporated herein by reference.

The process for preparing the compound of Formula (II) can be carried out
in the presence of a base. Tertiary amines such as triethylamine, tri-n-butylamine,
diisopropylethylamine, pyridine, N, N-dimethylaniline, etc. may be used as the
base. Preferably, triethylamine or tri-n-butylamine is used.

The antisolvent that is added to crystallize out the compounds of Formula II
may be selected from hydrocarbons such as toluene, hexane and lower alkyl
ethers such as diethyl ether, diisopropyl ether, or mixture(s) thereof.

Appropriate amounts of antisolvents may be added to crystallize out said
compounds. One to two times by volume of the antisolvent (with respect to
volume of the reaction solvent used) is usually sufficient to obtain the crystalline
compounds in desired yield and purity.

The compounds of Formula II may be converted to cefdinir by conventional methods for removal of the trityl group i.e. acid hydrolysis. However, an important characteristic of the compound of the present invention is that the removal of the trityl group requires very mild conditions. The p-toluene sulfonic acid addition salt provided by U.S. Patent No. 6,093,814 does not undergo complete hydrolysis without addition of an acid. However, the conversion of compounds of Formula II to cefdinir may be easily achieved either without use of any acid under reflux temperature, or with an acid at ambient temperature.

Conversion of the compound of Formula II to cefdinir is performed in a suitable solvent. Suitable solvents include any solvent, which is inert under the reaction conditions and may be selected from the solvents such as dichloromethane, ethylacetate, toluene, acetonitrile, tetrahydrofuran, methanol, isopropanol, water and mixture(s) thereof.

Suitable acid for the conversion include an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, etc; a lewis acid such as boron trifluoride, ferrous chloride, stannous chloride, zinc chloride, etc., an organic acid such as acetic acid, formic acid, trifluoroacetic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc; or an acidic hydrogen ion exchange resin.

Cefdinir obtained by the process of the present invention has a purity greater than 99% and assay greater than 97%. The mild conditions employed for hydrolysis prevent degradation and polymerization of the product.

Detailed Description of the Invention

In the following section preferred embodiments are described by way of examples to illustrate the process of the invention. However, these are not intended in any way to limit the scope of the present invention. Several variants of these examples would be evident to persons ordinarily skilled in the art.

EXAMPLE 1

7β-[2-(2-aminothiazol-4-yl)-2(Z)-trityloximino]acetamido]-3-vinyl-3-cephem-4-carboxylic acid, sulfuric acid salt, 3 N, N-dimethylacetamide solvate

5 7-amino-3-vinyl-3-cephem-4-carboxylic acid (10g) was added to N, N-dimethylacetamide (100ml) followed by the addition of 2-benzothiazolyl (Z)-2-(2-aminothiazol-4-yl)-2-trityloxyiminothioacetate (28.2g). The reaction mixture was cooled to 10-15°C and tri-n-butylamine (17.2g) was added in 20-30 minutes at 10-15°C. The reaction mixture was stirred at ambient temperature for 6-7 hours for
10 completion of reaction. Thereafter, it was cooled to -10°C and sulfuric acid (13.4g) was added dropwise in 30 minutes below 0°C. Toluene (100ml) was added to the reaction mixture under cooled condition followed by the addition of hexane (100ml). Temperature of the reaction mixture was raised to 35-40°C for crystallization to take place. The temperature was maintained at 35-40°C for 30
15 minutes. The precipitate thus obtained was filtered and washed with toluene and then dried to obtain 41.9 g (yield: 95%) of the title compound as cream colored crystals.

HPLC purity: 98.7%, m.p. = 132-135°C,

20 Sulfate content (chemical method) = 9.86% (w/w),

N, N-Dimethylacetamide content (GC) = 25.2% (w/w)

IR (KBr, cm^{-1}) = 3064, 1778, 1688, 1626, 1358, 1195

$^1\text{H-NMR}$ (300 MHz, DMSO-d_6) δ : 1.95 (9H, s), 2.76 (9H, s), 2.9(9H, s), 3.6 - 3.9 (2H, dd), 5.2-5.3 (2H, m), 5.5 - 5.6 (1H, d), 6.7(1H, s), 6.9 (1H, m), 7.1- 7.3 (17H,

25 m), 10.02 - 10.05 (1H, d)

Figure 1 shows the x-ray powder diffraction pattern of a sample prepared according to Example 1.

EXAMPLE 2

30 7β-[2-(2-aminothiazol-4-yl)-2(Z)-(trityloxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid, methanesulfonic acid salt, 3 N, N-dimethylacetamide solvate

7-amino-3-vinyl-3-cephem-4-carboxylic acid (10g) was added to N, N-dimethylacetamide (150ml) followed by the addition of 2-benzothiazolyl (Z)-2-(2-aminothiazol-4-yl)-2-trityloxyiminothioacetate (26.8g). Tri-n-butylamine (16.78g) was added to the reaction mixture at 10-15°C. The reaction mixture was stirred at room temperature for 7-8 hours for completion of reaction. Anhydrous methanesulfonic acid (13g) was added to the reaction mass below 10°C in 15-20 min followed by the addition of diisopropyl ether (150ml). The reaction mixture was warmed to 30-35°C for crystallization to take place. The precipitate thus obtained was filtered and washed with diisopropyl ether and then dried to obtain 38.5g (yield: 96%) of the title compound as off-white crystals.

HPLC purity : 99.3%, m.p. = 125-127°C, N, N-Dimethylacetamide content (by GC) = 25% (w/w)

IR (KBr, cm^{-1}) = 3062, 1779, 1689, 1620

$^1\text{H-NMR}$ (300 MHz, DMSO-d_6) δ : 1.95 (9H, s), 2.3 (3H, s), 2.7 (9H, s), 2.9 (9H, s), 3.6 – 3.9 (2H, dd), 5.2-5.3 (2H, m), 5.6 (1H, d), 5.9 (1H, m), 6.8 (1H, s), 6.9 (1H, s), 7.2-7.3 (17H, m), 10.05 – 10.08 (1H, d)

Figure 2 shows the x-ray powder diffraction pattern of a sample prepared according to Example 2.

EXAMPLE 3

7 β -[2-(2-aminothiazol-4-yl)-2(Z)-(trityloxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid, methanesulfonic acid salt, 2 N, N-dimethylacetamide solvate

7-amino-3-vinyl-3-cephem-4-carboxylic acid (15g) was added to N, N-dimethylacetamide (225ml) followed by the addition of 2-benzothiazolyl (Z)-2-(2-aminothiazol-4-yl)-2-trityloxyiminothioacetate (45g). Tri-n-butylamine (27g) was added to the reaction mixture at 10-15°C. The reaction mixture was stirred at 25 to 30°C for 7-8 hours for completion of reaction. Anhydrous methanesulfonic acid (210g) was added to the reaction mass below 0°C in 15-20 min followed by the addition of diisopropyl ether (450ml). The reaction mixture was warmed to

38-40°C and stirred for 45 minutes for crystallization to take place. The suspension was then cooled to 25 to 30°C and further stirred for one hour. The precipitate thus obtained was filtered, washed with diisopropyl ether and then dried to obtain 56.7g (yield: 94.2%) of the title compound as off-white crystals.

5

HPLC purity : 96.8%, , N, N-Dimethylacetamide content (by GC) = 21.2% (w/w)

EXAMPLE 4

7β-[2-(2-aminothiazol-4-yl)-2-(Z)-trityloxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid

10

7β-[2-(2-aminothiazol-4-yl)-2-(Z)-trityloxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid, sulfuric acid salt, 3 N, N-dimethylacetamide solvate (25g) obtained from example 1 was added to methanol (100ml). The reaction mixture was refluxed for 3.0 hours and thereafter methanol was recovered under reduced pressure. The pH of the concentrated mass was adjusted to 6.5 – 7.0 by slow addition of saturated solution of sodium bicarbonate. The aqueous layer so obtained was washed with ethylacetate (2x100ml) followed by the addition of dichloromethane (100ml). The resultant aqueous layer was degassed and treated with activated carbon under vacuum for 30 minutes, filtered through a celite and washed with water. The pH of aqueous layer was adjusted to 2.4-2.8 with 6N hydrochloric acid to precipitate cefdinir at its isoelectric point. The crystals thus obtained were stirred at 25-30°C for 2.0 hours, filtered and washed with water and dried to obtain 9.31g of title compound as a cream coloured solid (yield: 94%).

20
25

HPLC purity : 99.57%

IR (KBr, cm^{-1}) = 3295, 3059, 1767, 1683, 1622, 1352, 1174

$^1\text{H-NMR}$ (300 MHz, DMSO-d_6) δ : 3.4-3.8 (2H, m), 5.18 (1H, d), 5.2-5.5 (2H, dd), 5.7 (1H, d), 6.6 (1H, s), 6.8 (m, 1H), 7.1 (2H, brs), 9.48 (1H, d), 11.34 (1H, s).

30

EXAMPLE 5

7 β -[2-(2-aminothiazol-4-yl)-2-(Z)-trityloxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid

5 7 β -[2-(2-aminothiazol-4-yl)-2-(Z)-trityloxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid, sulfuric acid salt, 3 N-N-dimethylacetamide solvate (25g) was added to dichloromethane (75ml) and followed by the addition of formic acid (5 ml, 98-100%) to get a clear solution. The reaction mixture was then stirred at room temperature for 3 hours. The reaction mixture was poured into a
10 saturated solution of sodium bicarbonate (150ml) and pH was adjusted to 6.5 – 7.0. The resultant layer was separated and aqueous layer was washed with dichloromethane (100ml), followed by degassing and treatment with activated carbon under vacuum for 30 minutes. The solution was then filtered through a cellite and washed with water. The pH of the clear aqueous layer was adjusted to
15 2.4 – 2.8 with 6 N hydrochloric acid to precipitate cefdinir at its isoelectric point. The crystals thus obtained were stirred at 25-30°C for 2.0 hours, filtered, washed with water and dried to obtain 9.2g of off white solid (yield: 92.8%).

HPLC purity : 99.7%, IR (KBr, cm⁻¹) = 3295, 3059, 1767, 1683, 1622, 1352, 1174

20 ¹H-NMR (300 MHz, DMSO-d₆) δ : 3.4-3.8 (2H, m), 5.18 (1H, d) 5.2-5.5 (2H, dd), 5.7 (1H, m), 6.6(1H, s), 6.8 (1H, m), 7.1 (2H, brs), 9.48 (1H, d), 11.34 (1H, s)

EXAMPLE 6

25 **7 β -[2-(2-aminothiazol-4-yl)-2-(Z)-trityloxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid**

To the suspension of 7 β -[2-(2-aminothiazol-4-yl)-2(Z)-
(trityloxyimino)acetamido]-3-vinyl-3-cephem-4-carboxylic acid, methanesulfonic acid salt, 3N, N-dimethylacetamide solvate (100g) in dichloromethane (300ml)
30 was added formic acid (30ml, 98-100%) and hydrochloric acid (10ml, 36%) at 10-15°C. The temperature of the mixture was raised to 20-25°C and stirred for 6-7 hours. The reaction mixture was then poured into a suspension of sodium

bicarbonate (85g) and water (600ml). The dichloromethane layer was then separated and the aqueous layer was washed with dichloromethane (300ml). The pH was adjusted to 5.0 with hydrochloric acid and treated with activated carbon. The aqueous layer was acidified to pH 2.5-3.0 with 4N hydrochloric acid. The
5 resulting precipitate was collected by filtration and dried to afford 29.0g of cefdinir (yield: 73%).

HPLC purity: 99.48%.

Assay (by HPLC): 97.4%


10

While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.


15

WE CLAIM:

1. A process for the preparation of cefdinir of Formula I,

**Formula I**


which comprises removing a trityl protecting group in a cefdinir intermediate of formula II,

**Formula II**

wherein A is sulfuric acid or methanesulfonic acid, $n = 2$ or 3 , DMAC is N, N-dimethylacetamide and Ph is phenyl, in the presence or absence of an acid.

2. The process according to claim 1 wherein the compound of Formula II is heated under reflux temperature without an acid to give cefdinir of Formula I.
3. The process according to claim 1 wherein the compound of Formula II is reacted with an acid to give cefdinir of Formula I.


4. The process according to claim 1 wherein the reaction is carried out in the presence of a suitable solvent.
5. The process according to claim 4 wherein the suitable solvent is selected from the group consisting of dichloromethane, ethylacetate, toluene, acetonitrile, tetrahydrofuran, methanol, isopropanol, and water.
6. The process according to claim 3 wherein the acid is an inorganic acid, a lewis acid, an organic acid, or an acidic hydrogen ion exchange resin.
7. The process according to claim 6 wherein the inorganic acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, hydroiodic acid, and sulfuric acid.
8. The process according to claim 6 wherein the lewis acid is selected from the group consisting of boron trifluoride, ferrous chloride, stannous chloride, and zinc chloride.
9. The process according to claim 6 wherein the organic acid is selected from the group consisting of acetic acid, formic acid, trifluoroacetic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.
10. A process for the preparation of compound of Formula II






Formula II

wherein A is sulfuric acid or methanesulfonic acid, $n = 2$ or 3 , DMAC is N, N-dimethylacetamide and Ph is phenyl, which comprises reacting a reactive ester having the following formula P(iv),


16

**Formula P(iv)**


in which Ph represents phenyl, Z represents



or




wherein R' represents C₁-C₄ alkyl or phenyl, with a 3-cephem derivative having the following formula P(v),

**Formula P(v)**

in a solvent comprising N, N-dimethylacetamide (DMAC) in the presence or absence of a base, and then adding sulfuric acid / methane sulfonic acid under cooling at about -10 to 0°C .

11. The process according to claim 10 wherein an antisolvent is added to precipitate the compound of Formula II.
12. The process according to claim 11 wherein the mixture is stirred at a temperature of about 30 to 45°C after the addition of antisolvent.
13. The process according to claim 11 wherein the antisolvent is selected from the group consisting of hydrocarbons such as toluene, hexane and lower alkyl ethers such as diethyl ether, diisopropyl ether, or mixture(s) thereof.
14. The process of claim 11 wherein an antisolvent is added in an amount which is one to two times by volume with respect to the volume of the reaction solvent.
15. The process according to claim 10 wherein a tertiary amine is used as the base.
16. The process according to claim 15 wherein the tertiary amine is triethylamine or tri-n-butylamine.
17. A crystalline cefdinir intermediate having the following formula II:



Formula II

wherein A is sulfuric acid or methanesulfonic acid, $n = 2$ or 3 , DMAC is N, N-dimethylacetamide and Ph is phenyl.

FIGURE 1





FIGURE 2



INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB02/01410

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D 501/22

US CL : 540/222

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 540/222

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS Online

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A ✓	WO 01/79211 A1 (OTSUKA KAGAKU KABUSHIKI KAISHA) 25 October 2001 (25.10.2001). See example 2.	1-17
A ✓	US 6,093,814 A (LEB et al.) 25 July 2000 (25.07.2000). See entire document.	1-17



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z"

document member of the same patent family

Date of the actual completion of the international search

30 May 2003 (30.05.2003)

Date of mailing of the international search report

28 JUL 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Patricia D. Roberts for
Mark L. Berch

Telephone No. 703-308-1235